Description
Edarbi (Azilsartan Medoxomil) Tablets 40 mg. №28
Ingredients:
Each tablet contains 40 mg of azilsartan medoxomil.
Mechanism of Action:
Edarbi works by blocking the action of angiotensin II, a hormone that constricts blood vessels, leading to decreased blood pressure.
Pharmacological Properties:
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to its receptors, resulting in vasodilation and decreased aldosterone secretion.
Indications for Use:
Edarbi is indicated for the treatment of hypertension in adults.
Contraindications:
Do not use Edarbi if you are pregnant, have severe renal impairment, or are allergic to azilsartan medoxomil.
Side Effects:
- Dizziness
- Fatigue
- Hypotension
- Hyperkalemia
Usage Instructions:
The recommended dosage is one 40 mg tablet once daily. Take Edarbi exactly as prescribed by your healthcare provider. It can be taken with or without food.
Benefits Compared to Analogues:
Edarbi has shown to have a lower risk of side effects compared to other similar drugs in the ARB class. It provides consistent and reliable blood pressure control.
Suitable Patient Groups:
Edarbi is suitable for adult patients with hypertension. It may also be used in specific cases for children and the elderly under close medical supervision.
Storage Conditions and Shelf Life:
Store Edarbi in a cool, dry place away from direct sunlight. Keep the tablets in their original packaging. Check the expiration date on the packaging and do not use after that date.
Packaging Description:
Edarbi tablets are packed in blister packs containing 28 tablets each. The packaging is designed to protect the tablets from moisture and light.
Clinical Evidence and Proven Effectiveness:
Clinical studies have shown that azilsartan medoxomil effectively reduces blood pressure in patients with hypertension. A study published in the American Journal of Hypertension demonstrated a significant decrease in both systolic and diastolic blood pressure compared to a placebo group. Edarbi has also been proven effective in combination with other antihypertensive medications, reducing the risk of cardiovascular events associated with hypertension.
